Anixa Biosciences Announce Keynote Speaker for SCTR Retreat 2026
Anixa Biosciences has made significant strides in the biotechnology field, particularly in the treatment and prevention of cancer. As part of their ongoing initiatives, the company is set to have Dr. Jose Conejo-Garcia, a distinguished Professor of Immunology at Duke University, serve as the keynote speaker at the South Carolina Clinical and Translational Research (SCTR) Institute Retreat in 2026. The event, themed Cell-Based Therapies from Discovery to Translation, will take place on March 6, 2026, and is expected to be a gathering point for leading professionals in research, clinical care, and the biotechnology industry. Dr. Conejo-Garcia is known for co-inventing Anixa's FSHR-mediated CAR-T therapy aimed at treating ovarian cancer. His keynote will highlight the ongoing Phase 1 clinical trial concerning liraltagene autoleucel (lira-cel), which utilizes the innovative therapy pioneered by his team. Lira-cel is uniquely designed to target the follicle-stimulating hormone receptor (FSHR) which is found on ovarian tumors and certain cancer cells while sparing healthy tissues. This promising treatment is currently being tested in adult women battling recurrent ovarian cancer who have not responded to previous therapies.
The SCTR Retreat is anticipated to feature discussions on groundbreaking approaches within cell therapy, immune therapy, and oncology. It will foster collaboration among top-tier experts, aimed at driving innovations in medicine. Anixa's dedication to advancing cancer therapies through collaborations with esteemed institutions like the Moffitt Cancer Center demonstrates their commitment to developing powerful immunotherapies. Based on chimeric endocrine receptor-T cell (CER-T) technology, lira-cel offers a novel therapeutic approach distinct from traditional CAR-T therapies.
In addition to their CAR-T innovations, Anixa is also progressing with vaccine technologies in collaboration with the Cleveland Clinic, targeting breast and ovarian cancers, and expanding their portfolio to address various malignancies, including lung, colon, and prostate cancers. Their forward-thinking model of partnering with leading research organizations enables the exploration of emerging technologies in complementary fields for potential development and commercialization.
The upcoming SCTR Retreat, featuring an influential figure such as Dr. Conejo-Garcia, underscores the excitement around new avenues in cancer treatment that are on the horizon. As the event approaches, healthcare professionals and stakeholders are watching closely for outcomes that could revolutionize therapeutic strategies against complex cancers. Anixa Biosciences continues to pioneer efforts in cancer research, promising solutions that may change the lives of countless individuals impacted by these diseases.
This event not only highlights the advancements in oncology but also emphasizes the importance of collaborative efforts in healthcare and research. The progress made in therapies like lira-cel showcases the potential for innovation in addressing unresolved challenges in cancer treatments. As such, attendees of the SCTR Retreat will not only gain insight into the future of cell-mediated therapies but will also be inspired by the profound impact of cooperative research in addressing the ongoing battle against cancer.
The SCTR Retreat is anticipated to feature discussions on groundbreaking approaches within cell therapy, immune therapy, and oncology. It will foster collaboration among top-tier experts, aimed at driving innovations in medicine. Anixa's dedication to advancing cancer therapies through collaborations with esteemed institutions like the Moffitt Cancer Center demonstrates their commitment to developing powerful immunotherapies. Based on chimeric endocrine receptor-T cell (CER-T) technology, lira-cel offers a novel therapeutic approach distinct from traditional CAR-T therapies.
In addition to their CAR-T innovations, Anixa is also progressing with vaccine technologies in collaboration with the Cleveland Clinic, targeting breast and ovarian cancers, and expanding their portfolio to address various malignancies, including lung, colon, and prostate cancers. Their forward-thinking model of partnering with leading research organizations enables the exploration of emerging technologies in complementary fields for potential development and commercialization.
The upcoming SCTR Retreat, featuring an influential figure such as Dr. Conejo-Garcia, underscores the excitement around new avenues in cancer treatment that are on the horizon. As the event approaches, healthcare professionals and stakeholders are watching closely for outcomes that could revolutionize therapeutic strategies against complex cancers. Anixa Biosciences continues to pioneer efforts in cancer research, promising solutions that may change the lives of countless individuals impacted by these diseases.
This event not only highlights the advancements in oncology but also emphasizes the importance of collaborative efforts in healthcare and research. The progress made in therapies like lira-cel showcases the potential for innovation in addressing unresolved challenges in cancer treatments. As such, attendees of the SCTR Retreat will not only gain insight into the future of cell-mediated therapies but will also be inspired by the profound impact of cooperative research in addressing the ongoing battle against cancer.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.